Strosberg Jonathan, Gardner Nancy, Kvols Larry
Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Pancreas. 2009 Apr;38(3):255-8. doi: 10.1097/MPA.0b013e3181917e4e.
Pancreatic endocrine carcinomas (PECAs) are uncommon, with an incidence of 1 per 100,000. Past studies of chemotherapy and hepatic arterial embolization have described median survival durations of approximately 2 to 3 years. Overall survival from time of diagnosis of metastases has never been reported in a large cohort of patients. Our objective was to evaluate the stage-specific prognosis of patients with metastatic PECAs and to assess the impact of clinical and pathologic prognostic factors.
We evaluated all cases of differentiated, metastatic PECAs seen at the H. Lee Moffitt Cancer Center between the years 1999 and 2003, measuring survival from time of diagnosis of metastases.
Ninety cases of metastatic PECAs were identified. Median overall survival was 70 months, and the 5-year survival rate was 56%. Age, sex, and tumor type (functional vs nonfunctional) did not impact prognosis. Tumor grade, however, was highly prognostic for survival.
Median overall survival is 70 months (5.8 years) among patients with metastatic PECAs. This prolonged survival duration may reflect the impact of multimodality treatments. Tumor grade (low vs intermediate grade) represents a highly significant prognostic factor.
胰腺内分泌癌（PECAs）并不常见，发病率为十万分之一。既往关于化疗和肝动脉栓塞的研究描述的中位生存期约为2至3年。从未有大量患者队列报道过从转移诊断时间起的总生存期。我们的目的是评估转移性PECAs患者的分期特异性预后，并评估临床和病理预后因素的影响。
我们评估了1999年至2003年间在H. Lee Moffitt癌症中心所见的所有分化型转移性PECAs病例，从转移诊断时间开始计算生存期。
共识别出90例转移性PECAs病例。中位总生存期为70个月，5年生存率为56%。年龄、性别和肿瘤类型（功能性与非功能性）不影响预后。然而，肿瘤分级对生存期具有高度预后价值。
转移性PECAs患者的中位总生存期为70个月（5.8年）。这种延长的生存期可能反映了多模式治疗的影响。肿瘤分级（低级别与中级别的）是一个非常重要的预后因素。
